Hypoxia imaging with 18F-FAZA PET/CT predicts radiotherapy response in esophageal adenocarcinoma xenografts
Authors:
- Elodie MelsensEMElodie Melsens
- Elly De VlieghereEVElly De Vlieghere
- Benedicte DescampsBDBenedicte Descamps
- Christian VanhoveCVChristian Vanhove
- Ken KersemansKKKen Kersemans
- Filip De VosFVFilip De Vos
- Ingeborg GoethalsIGIngeborg Goethals
- Boudewijn BransBBBoudewijn Brans
- Olivier De WeverOWOlivier De Wever
- Wim CeelenWim Ceelen
- Piet PattynPPPiet Pattyn
Open Access
- 7 March 2018
- journal article
- research article
- Published by Springer Nature in Radiation Oncology
- Vol. 13 (1) , 1-8
Abstract
Esophageal cancer is an aggressive disease with poor survival rates. A more patient-tailored approach based on predictive biomarkers could improve outcome. We aimed to predict radiotherapy (RT) response by imaging tumor hypoxia with 18F-FAZA PET/CT in an esophageal adenocarcinoma (EAC) mouse model. Additionally, we investigated the radiosensitizing effect of the hypoxia modifier nimorazole in vitro and in vivo. In vitro MTS cell proliferation assays (OACM5 1.C SC1, human EAC cell line) were performed under normoxic and hypoxic (< 1%) conditions: control (100 μL PBS), nimorazole, irradiation (5, 10 or 20 Gy) with or without nimorazole. In vivo, subcutaneous xenografts were induced in nude mice (OACM5 1.C SC1). Treatment was given daily for 5 consecutive days: (A) control (600 μl NaCl 0.9% intraperitoneally (IP)) (N = 5, n = 7), (B) RT (5 Gy/d) (N = 11, n = 20), (C) combination (nimorazole (200 mg/kg/d IP) 30 min before RT) (N = 13, n = 21). N = number of mice, n = number of tumors. 18F-FAZA PET/CT was performed before treatment and tumor to background (T/B) ratios were calculated. Relative tumor growth was calculated and tumor sections were examined histologically (hypoxia, proliferation). A T/B ≥ 3.59 on pre-treatment 18F-FAZA PET/CT was predictive for worse RT response (sensitivity 92.3%, specificity 71.4%). Radiation was less effective in hypoxic tumors (T/B ≥ 3.59) compared to normoxic tumors (T/B < 3.59) (P = 0.0025). In vitro, pre-treatment with nimorazole significantly decreased hypoxic radioresistance (P < 0.01) while in vivo, nimorazole enhanced the efficacy of RT to suppress cancer cell proliferation in hypoxic tumor areas (Ki67, P = 0.064), but did not affect macroscopic tumor growth. Tumor tissue hypoxia as measured with 18F-FAZA PET/CT is predictive for RT response in an EAC xenograft model. The radiosensitizing effect of nimorazole was questionable and requires further investigation.Keywords
This publication has 33 references indexed in Scilit:
- Improved xenograft efficiency of esophageal adenocarcinoma cell lines through in vivo selectionOncology Reports, 2017
- Baseline [18F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft ModelMolecular Imaging and Biology, 2016
- Prognostic value of 18F‐fluoroazomycin arabinoside PET/CT in patients with advanced non‐small‐cell lung cancerCancer Science, 2015
- Potential role of hypoxia imaging using 18F-FAZA PET to guide hypoxia-driven interventions (carbogen breathing or dose escalation) in radiation therapyRadiotherapy and Oncology, 2014
- PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.2014
- Clinicopathological and prognostic significance of hypoxia-inducible factor-1α in esophageal squamous cell carcinoma: a meta-analysisTumor Biology, 2014
- Measuring tumor hypoxia with 18F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical studyDiseases of the Esophagus, 2011
- Hypofractionation Results in Reduced Tumor Cell Kill Compared to Conventional Fractionation for Tumors With Regions of HypoxiaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Hypoxia in cancer: significance and impact on clinical outcomeCancer and Metastasis Reviews, 2007
- Expression of Carbonic Anhydrase IX (CA IX), a Hypoxia-Related Protein, Rather Than Vascular-Endothelial Growth Factor (VEGF), a Pro-Angiogenic Factor, Correlates With an Extremely Poor Prognosis in Esophageal and Gastric AdenocarcinomasAnnals of Surgery, 2006